OncoMatch/Clinical Trials/NCT06440135
Ziftomenib Maintenance Post Allo-HCT
Is NCT06440135 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Ziftomenib for acute myeloid leukemia.
Treatment: Ziftomenib — The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this study is: • Ziftomenib
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KMT2A (MLL) rearrangement
Required: NPM1 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic hematopoietic cell transplant — first
Will undergo first allogeneic HCT for their malignancy
Cannot have received: menin inhibitor
Exception: permitted unless AML relapse or progression occurred while on menin inhibitor prior to transplant
Treatment with a menin inhibitor prior to transplant is permitted. However, patients who experienced AML relapse or progression while being treated with a menin inhibitor prior to transplant are ineligible.
Lab requirements
Kidney function
Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula)
Liver function
AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional ULN; Total bilirubin < 1.5 x institutional ULN (except Gilbert's syndrome < 5 x ULN)
Cardiac function
LVEF must be ≥50%, as measured by MUGA scan or echocardiogram
Participants must have normal organ and function as defined below: AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN); Total bilirubin < 1.5 x institutional ULN (with the exception of subjects with a history of Gilbert's syndrome, for which the total bilirubin must be < 5 x ULN); Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula); LVEF must be ≥50%, as measured by MUGA scan or echocardiogram.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Ohio State University Wexner Medical Center- James Cancer Hospital · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify